- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Heart failure
- Meeting Date: November 2020
- Public Summary Document (PSD) November 2020 PBAC Meeting - (PDF 1318KB)
- Public Summary Document (PSD) November 2020 PBAC Meeting - (Word 109KB)
Sacubitril with valsartan – November 2020
Sacubitril with valsartan; Tablet containing sacubitril 24.3 mg and valsartan 25.7 mg, Tablet containing sacubitril 48.6 mg and valsartan 51.4 mg, Tablet containing sacubitril 97.2 mg and valsartan 102.8 mg; Entresto®
Last updated
19 March 2021
